{
"info": {
"nct_id": "NCT04687982",
"official_title": "Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).",
"inclusion_criteria": "1. Written, signed informed consent;\n2. Adult patients aged ≥18 years;\n3. Patients who underwent haploidentical transplantation with PT-Cy for haematological diseases since no more than 56 days;\n4. Patient who received myeloablative conditioning regimen, reduced intensity conditioning regimens, or non-myeloablative conditioning regimens;\n5. Availability of haploidentical donor (defined as those with ≥ 2 differences within one HLA haplotype) who agree to donate peripheral blood cells by leukapheresis and able to donate the day before the day planned for infusion (or up to - 7 days);\n6. GVHD/HVG prophylaxis consists in Cyclophosphamide: 50 mg/kg/day, day +3 and +4, Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Presence of grade 2-4 acute GVHD;\n2. Uncontrolled bacterial, viral or fungal infection;\n3. Aplasia defined as ANC less than 500/L;\n4. Evidence of disease progression after transplantation;\n5. Current participation in another clinical study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "1. Written, signed informed consent;",
"criterions": [
{
"exact_snippets": "Written, signed informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "form",
"expected_value": "written"
}
},
{
"exact_snippets": "Written, signed informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "signature",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Written, signed informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "form",
"expected_value": "written"
}
},
{
"exact_snippets": "Written, signed informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "signature",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "2. Adult patients aged ≥18 years;",
"criterions": [
{
"exact_snippets": "Adult patients aged ≥18 years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Adult patients aged ≥18 years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
}
]
}
},
{
"identified_line": {
"line": "3. Patients who underwent haploidentical transplantation with PT-Cy for haematological diseases since no more than 56 days;",
"criterions": [
{
"exact_snippets": "Patients who underwent haploidentical transplantation",
"criterion": "haploidentical transplantation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "PT-Cy",
"criterion": "PT-Cy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "haematological diseases",
"criterion": "haematological diseases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "since no more than 56 days",
"criterion": "time since transplantation",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 56,
"unit": "days"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Patients who underwent haploidentical transplantation",
"criterion": "haploidentical transplantation",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "PT-Cy",
"criterion": "PT-Cy",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "haematological diseases",
"criterion": "haematological diseases",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "since no more than 56 days",
"criterion": "time since transplantation",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 56,
"unit": "days"
}
}
}
]
}
},
{
"identified_line": {
"line": "4. Patient who received myeloablative conditioning regimen, reduced intensity conditioning regimens, or non-myeloablative conditioning regimens;",
"criterions": [
{
"exact_snippets": "Patient who received myeloablative conditioning regimen",
"criterion": "myeloablative conditioning regimen",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Patient who received ... reduced intensity conditioning regimens",
"criterion": "reduced intensity conditioning regimens",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Patient who received ... non-myeloablative conditioning regimens",
"criterion": "non-myeloablative conditioning regimens",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Patient who received myeloablative conditioning regimen",
"criterion": "myeloablative conditioning regimen",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Patient who received ... reduced intensity conditioning regimens",
"criterion": "reduced intensity conditioning regimens",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Patient who received ... non-myeloablative conditioning regimens",
"criterion": "non-myeloablative conditioning regimens",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "5. Availability of haploidentical donor (defined as those with ≥ 2 differences within one HLA haplotype) who agree to donate peripheral blood cells by leukapheresis and able to donate the day before the day planned for infusion (or up to - 7 days);",
"criterions": [
{
"exact_snippets": "Availability of haploidentical donor",
"criterion": "haploidentical donor",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "haploidentical donor (defined as those with ≥ 2 differences within one HLA haplotype)",
"criterion": "HLA haplotype differences",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "differences"
}
}
},
{
"exact_snippets": "donor ... agree to donate peripheral blood cells by leukapheresis",
"criterion": "donor agreement to donate",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "donor ... able to donate the day before the day planned for infusion (or up to - 7 days)",
"criterion": "donation timing",
"requirement": {
"requirement_type": "timing",
"expected_value": "day before infusion or up to -7 days"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Availability of haploidentical donor",
"criterion": "haploidentical donor",
"requirement": {
"requirement_type": "availability",
"expected_value": true
}
},
{
"exact_snippets": "haploidentical donor (defined as those with ≥ 2 differences within one HLA haplotype)",
"criterion": "HLA haplotype differences",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "differences"
}
}
}
]
},
{
"exact_snippets": "donor ... agree to donate peripheral blood cells by leukapheresis",
"criterion": "donor agreement to donate",
"requirement": {
"requirement_type": "agreement",
"expected_value": true
}
},
{
"exact_snippets": "donor ... able to donate the day before the day planned for infusion (or up to - 7 days)",
"criterion": "donation timing",
"requirement": {
"requirement_type": "timing",
"expected_value": "day before infusion or up to -7 days"
}
}
]
}
},
{
"identified_line": {
"line": "6. GVHD/HVG prophylaxis consists in Cyclophosphamide: 50 mg/kg/day, day +3 and +4, Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35.",
"criterions": [
{
"exact_snippets": "Cyclophosphamide: 50 mg/kg/day, day +3 and +4",
"criterion": "Cyclophosphamide dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 50,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Cyclophosphamide: 50 mg/kg/day, day +3 and +4",
"criterion": "Cyclophosphamide dosage",
"requirement": {
"requirement_type": "administration days",
"expected_value": [
"day +3",
"day +4"
]
}
},
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 3,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "administration period",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 5,
"unit": "day"
},
{
"operator": "<=",
"value": 100,
"unit": "day"
}
]
}
}
},
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "tapering period",
"expected_value": "2 months"
}
},
{
"exact_snippets": "Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35",
"criterion": "Mycophenolate mofetil dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 45,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35",
"criterion": "Mycophenolate mofetil dosage",
"requirement": {
"requirement_type": "administration period",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 5,
"unit": "day"
},
{
"operator": "<=",
"value": 35,
"unit": "day"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Cyclophosphamide: 50 mg/kg/day, day +3 and +4",
"criterion": "Cyclophosphamide dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 50,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Cyclophosphamide: 50 mg/kg/day, day +3 and +4",
"criterion": "Cyclophosphamide dosage",
"requirement": {
"requirement_type": "administration days",
"expected_value": [
"day +3",
"day +4"
]
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 3,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "administration period",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 5,
"unit": "day"
},
{
"operator": "<=",
"value": 100,
"unit": "day"
}
]
}
}
},
{
"exact_snippets": "Cyclosporine A: 3 mg/kg/day from day +5 to day +100, with tapering in 2 months",
"criterion": "Cyclosporine A dosage",
"requirement": {
"requirement_type": "tapering period",
"expected_value": "2 months"
}
}
]
},
{
"and_criteria": [
{
"exact_snippets": "Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35",
"criterion": "Mycophenolate mofetil dosage",
"requirement": {
"requirement_type": "dosage",
"expected_value": {
"operator": "=",
"value": 45,
"unit": "mg/kg/day"
}
}
},
{
"exact_snippets": "Mycophenolate mofetil: 45 mg/kg/day, from day +5 to day +35",
"criterion": "Mycophenolate mofetil dosage",
"requirement": {
"requirement_type": "administration period",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 5,
"unit": "day"
},
{
"operator": "<=",
"value": 35,
"unit": "day"
}
]
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "1. Presence of grade 2-4 acute GVHD;",
"criterions": [
{
"exact_snippets": "Presence of grade 2-4 acute GVHD",
"criterion": "acute GVHD",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Presence of grade 2-4 acute GVHD",
"criterion": "acute GVHD",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "grade"
},
{
"operator": "<=",
"value": 4,
"unit": "grade"
}
]
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Presence of grade 2-4 acute GVHD",
"criterion": "acute GVHD",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "Presence of grade 2-4 acute GVHD",
"criterion": "acute GVHD",
"requirement": {
"requirement_type": "severity",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 2,
"unit": "grade"
},
{
"operator": "<=",
"value": 4,
"unit": "grade"
}
]
}
}
}
]
}
},
{
"identified_line": {
"line": "2. Uncontrolled bacterial, viral or fungal infection;",
"criterions": [
{
"exact_snippets": "Uncontrolled bacterial ... infection",
"criterion": "bacterial infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
},
{
"exact_snippets": "Uncontrolled ... viral ... infection",
"criterion": "viral infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
},
{
"exact_snippets": "Uncontrolled ... fungal infection",
"criterion": "fungal infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"exact_snippets": "Uncontrolled bacterial ... infection",
"criterion": "bacterial infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
},
{
"exact_snippets": "Uncontrolled ... viral ... infection",
"criterion": "viral infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
},
{
"exact_snippets": "Uncontrolled ... fungal infection",
"criterion": "fungal infection",
"requirement": {
"requirement_type": "control",
"expected_value": false
}
}
]
}
},
{
"identified_line": {
"line": "3. Aplasia defined as ANC less than 500/L;",
"criterions": [
{
"exact_snippets": "Aplasia defined as ANC less than 500/L",
"criterion": "ANC (Absolute Neutrophil Count)",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 500,
"unit": "/L"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Aplasia defined as ANC less than 500/L",
"criterion": "ANC (Absolute Neutrophil Count)",
"requirement": {
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 500,
"unit": "/L"
}
}
}
]
}
},
{
"identified_line": {
"line": "4. Evidence of disease progression after transplantation;",
"criterions": [
{
"exact_snippets": "Evidence of disease progression after transplantation",
"criterion": "disease progression after transplantation",
"requirement": {
"requirement_type": "evidence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Evidence of disease progression after transplantation",
"criterion": "disease progression after transplantation",
"requirement": {
"requirement_type": "evidence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "5. Current participation in another clinical study.",
"criterions": [
{
"exact_snippets": "Current participation in another clinical study",
"criterion": "participation in another clinical study",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Current participation in another clinical study",
"criterion": "participation in another clinical study",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}